Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals
K Dobrowolska, M Brzdęk, P Rzymski… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction With the introduction of highly effective and safe therapies with next-generation
direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection …
direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection …
Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
R Flisiak, D Zarębska-Michaluk, H Berak… - Clinical and …, 2023 - termedia.pl
Results: The studied population consisted of 269 patients, of whom 208 were treated with
the double (P2) and 61 with the triple (P3) pangenotypic option. No statistically significant …
the double (P2) and 61 with the triple (P3) pangenotypic option. No statistically significant …
[HTML][HTML] Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral-experienced hepatitis C virus patients: a systematic review and meta …
P Devan, KLA Tiong, JE Neo, BP Mohan… - Viruses, 2023 - mdpi.com
About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-
acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of …
acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of …
Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
JC Ruiz‐Cobo, J Llaneras, X Forns… - Alimentary …, 2024 - Wiley Online Library
Background Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended
rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals …
rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals …
[HTML][HTML] Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs
H Omar, MHA Maksoud, AA Goma, EA Hassan… - Egyptian Liver …, 2024 - Springer
Background and aims NS5A inhibitors are an important option for treating chronic HCV-GT4
patients. Retreatments after NS5A-based DAAs failure are limited. We aimed to determine …
patients. Retreatments after NS5A-based DAAs failure are limited. We aimed to determine …
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India
Background and aim Hepatitis C virus (HCV) treatment fails to achieve sustained virological
response at 12 weeks (SVR12) in 5–10% and requires retreatment with second-line drugs …
response at 12 weeks (SVR12) in 5–10% and requires retreatment with second-line drugs …
[HTML][HTML] SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024
AS Alghamdi, H Alghamdi, HA Alserehi… - Saudi Journal of …, 2024 - journals.lww.com
Hepatitis C virus (HCV) infection has been a major global health concern, with a significant
impact on public health. In recent years, there have been remarkable advancements in our …
impact on public health. In recent years, there have been remarkable advancements in our …